- Home
- GOSS vs CCAP Comparison
GOSS vs CCAP Comparison
Compare GOSS & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- CCAP
- Stock Information
- Founded
- GOSS 2015
- CCAP 2015
- Country
- GOSS United States
- CCAP United States
- Employees
- GOSS N/A
- CCAP N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- CCAP Finance: Consumer Services
- Sector
- GOSS Health Care
- CCAP Finance
- Exchange
- GOSS Nasdaq
- CCAP Nasdaq
- Market Cap
- GOSS 586.6M
- CCAP 582.2M
- IPO Year
- GOSS 2019
- CCAP N/A
- Fundamental
- Price
- GOSS $2.94
- CCAP $15.94
- Analyst Decision
- GOSS Strong Buy
- CCAP Buy
- Analyst Count
- GOSS 4
- CCAP 4
- Target Price
- GOSS $8.50
- CCAP $16.38
- AVG Volume (30 Days)
- GOSS 3.3M
- CCAP 216.4K
- Earning Date
- GOSS 11-06-2025
- CCAP 08-13-2025
- Dividend Yield
- GOSS N/A
- CCAP 10.85%
- EPS Growth
- GOSS N/A
- CCAP N/A
- EPS
- GOSS N/A
- CCAP 1.19
- Revenue
- GOSS $40,237,000.00
- CCAP $183,172,000.00
- Revenue This Year
- GOSS N/A
- CCAP N/A
- Revenue Next Year
- GOSS $30.65
- CCAP $1.65
- P/E Ratio
- GOSS N/A
- CCAP $13.43
- Revenue Growth
- GOSS N/A
- CCAP N/A
- 52 Week Low
- GOSS $0.66
- CCAP $13.54
- 52 Week High
- GOSS $2.98
- CCAP $20.19
- Technical
- Relative Strength Index (RSI)
- GOSS 76.74
- CCAP 75.62
- Support Level
- GOSS $2.41
- CCAP $15.46
- Resistance Level
- GOSS $2.71
- CCAP $15.38
- Average True Range (ATR)
- GOSS 0.19
- CCAP 0.21
- MACD
- GOSS 0.04
- CCAP 0.06
- Stochastic Oscillator
- GOSS 96.37
- CCAP 90.82
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.